N
Novavax, Inc. (NVAX)
NMS – Real Time Price. Currency in USD
8.45
-0.50 (-5.59%)
At close: Mar 27, 2026, 4:00 PM EDT
8.52
+0.07 (0.83%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
8.45
-0.50 (-5.59%)
At close: Mar 27, 2026, 4:00 PM EDT
8.52
+0.07 (0.83%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Name | Position |
|---|---|
| Luis Sanay C.F.A. | Vice President of Investor Relations |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer |
| Mr. John Charles Jacobs M.B.A. | President, CEO & Director |
| Mr. Mark J. Casey Esq. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Richard P. Crowley | Executive VP & COO |
| Mr. Troy Morgan Esq., J.D. | Senior VP, Deputy General Counsel & Chief Compliance Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-20 | 8-K | tm263587d1_8k.htm |
| 2026-01-12 | 8-K | tm262897d1_8k.htm |
| 2025-11-06 | 8-K | nvax-20251106.htm |
| 2025-11-04 | 8-K | tm2530132d1_8k.htm |
| 2025-10-22 | 8-K | tm2529188d1_8k.htm |
| 2025-10-07 | 8-K | tm2528134d1_8k.htm |
| 2025-08-27 | 8-K | tm2524511d1_8k.htm |
| 2025-08-21 | 8-K | tm2524045d1_8k.htm |
| 2025-08-06 | 8-K | nvax-20250806.htm |
| 2025-06-24 | 8-K | tm2518733d1_8k.htm |
| Ms. Elaine O'Hara |
| Executive VP & Chief Strategy Officer |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations |
| Ms. Silvia Taylor M.B.A. | Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden |